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ABSTRACT
Objectives: A proper implantation of trophoblastic cells and an appropriate metalloproteinases activity is required to 
cause disintegration of basal membranes of cells. The activity of tissue matrix metaloproteinases can be inhibited by their 
matrix inhibitors — TIMP-s. Survivin is a member of inhibitor of apoptosis proteins family (IAP), that suppresses caspase 
activation, influences VEGF expression and promotes proliferative action of endothelial cells.
Material and methods: The aim of the study was to assess concentrations of two independent anti-apoptotic fac-
tors. TIMP-1 and survivin in serum of women in their third trimester of pregnancy and in umbilical cord blood of neonates 
– drawn separately from veins and arteries. The study group consisted of 29 pregnant women in physiological pregnancy 
and with correct fetal development, in gestational age between 37 to 40 weeks of gestation. Blood used in the study was 
collected from maternal cubital fossa veins and from neonatal umbilical cords (from veins and from arteries separately). 
The research was conducted using TIMP-1 and Survivin ELISA kits from R & D Systems according to manufacturers’ recom-
mendations and protocols. 
Results: The concentrations of TIMP-1 were similar and independent of the source of blood samples. Arterial values of 
TIMP-1 in umbilical cord compared to maternal and fetal veins were slightly lower, but no statistical difference was found. 
The mean concentrations of Survivin were comparable but we found that in some cases the results in cord blood serum 
in both vessels-vein and arteries were almost negative. Arterial values of Survivin in umbilical cord compared to maternal 
blood were higher, but no statistical difference was found.
Conclusions: In III-rd trimester of pregnancy parameters of Timp-1 and Survivin — anti-apoptotic substances concentration 
were similar in maternal and cord blood in both artery and vein. We found no increased activity of selected antiapoptotic 
factors.
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INTRODUCTION
Fetal development in physiological pregnancy depends 
on many external and internal factors. One of the most 
important factors is a proper trophoblast implantation that 
ensures proper placental function later in pregnancy and 
therefore correct fetal development. 
Common complications caused by an incorrect implan-
tation may include pregnancy induced hypertension and 
intrauterine fetal growth restriction. 
Among many factors determining successful tropho-
blast implantation, alterations in extracellular matrix struc-
ture and the disintegration of basal membranes of cells 
play a crucial role. Those phenomena are a result of matrix 
metalloproteinase activity and are determined by the pres-
ence of zinc particle in their enzymatic center. Structural and 
regulative functions of extracellular matrix are associated 
with the presence of proteins and polysaccharides from 
which they are composed [1, 2].
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Metalloproteinase (MMP) family is involved in down 
regulation of organism’s development, homeostasis, heal-
ing, reconstruction of tissues and angiogenesis.
MMPs are stimulated by cytokines as a result of orga- 
nisms’ reaction to inflammatory processes or cell damage [3].
Metalloproteinase activation begins with a detachment 
of pro-peptides and an exposure of the enzymatic center in 
the presence of other activated metalloproteinases or serine 
proteases and by altering the special structure of the metallo-
proteinase active center through a reaction with SH group [4]. 
Metalloproteinase activation results in an increased cy-
tokine release and subsequent intracellular matrix collagen 
degradation allowing a leucocyte penetration to the inflam-
matory sources and inflammatory process restriction [5].
The biological action of metaloproteinases is regulated 
through different interactions with proteolytic enzymes in-
hibitors and specific inhibitors — tissue metalloproteinase 
inhibitors [TIMP]. Among the four well known tissue metal-
loproteinases inhibitors, TIMP-1 shows strong blocking action 
on MMP-1 and MMP-9, and a slightly weaker effect on MMP-2. 
In addition to the effect of TIMP on the activity of other 
metalloproteinases, it also exhibits anti-apoptotic and 
pro-proliferative action in organogenesis [6].
Metalloproteinase and their specific inhibitors — TIMP 
create a proteolytic system that constructs a sensitive ba- 
lance. If perturbed, it leads to an increased extracellular 
matrix decomposition and other proteolytic reactions in 
the process of placental implantation and placental an-
giogenesis.
Swierczewski found lower expression of one the TIMP 
markers [TIMP-2] in a group of healthy pregnant patients 
comparing to the group of IUGR [7].
Survivin is the smallest protein of anti-apoptotic effect 
(IAP- inhibitor of apoptosis protein), that inhibits caspase 
activation. It has been confirmed that the inhibition of Sur-
vivin activation path leads to an increase of apoptosis which 
in neoplastic disorders could retard hyperplasia.
Presence of Survivin was not only found in neoplastic 
cells but also in embryonic cells. In mature cells no expres-
sion of Survivin was found. Its activity probably dependent 
on p53 protein is observed at G2 stage of cell cycle, acting as 
a down regulator of mitotic processes by affecting tubulin 
[8]. As shown by Tamm, Survivin decreases two paths of 
apoptosis-through Bax and through Fas [9]. Among the 
known Survivin isoforms, variant-2 causes an increase of 
angiogenesis process. Survivin affects VEGF expression and 
promotes endothelial cells proliferation [10].
Control of apoptotic processes seems to be a main 
mechanism responsible for immune-suppression in preg-
nancy. Mediators of pro-apoptotic action released from 
placenta may cause T- lymphocytes apoptosis. An increase 
in the number of apoptotic leucocytes cohort [cd95+] in 
pregnant women compared to non-pregnant women con-
firms this observation.
Survivin plays a regulatory role in the development of 
placenta by controlling mechanisms of proliferation, apo- 
ptosis, angiogenesis, cell cycle control and trophoblast in-
vasion [11]. Deregulation of these processes presumably 
leads to placental function disturbances and is associated 
with various pregnancy complications. Different matrix 
metaloproteinases (MMPs), their inhibitors and Survivin 
can affect the trophoblast implantation process and later 
placental function.
OBJECTIVES
The main aim of the study was to evaluate concentra-
tions of two independent antiapoptotic factors- TIMP-1 and 
Survivin in serum of pregnant women in the third trimester 
of pregnancy and in umbilical cord blood of neonates.
MATERIAL AND METHOD
The study was conducted in High Risk Pregnancy Unit 
Medical University Lodz in 2013–2015 with the consent of 
the University Bioethics Board (RNN/149/09/KE).
The study group consisted of 29 pregnant women in 
physiological pregnancy and normal fetal development. 
Pregnancy age ranged between 37 to 40 weeks of gesta-
tion. Gestational age was estimated using the date of the 
last menstrual period and an early antenatal ultrasound. All 
of the patients delivered by elective caesarian section due 
to non-perinatal indications. 
Vein blood was collected 2 to 4 hours before the planned 
caesarian section from cubital fossa veins and from umbilical 
cord separately from vein and from arteries after a neonate 
was separated from placental part of umbilical cord. The 
volume of all blood samples was no less than 5 mL each. 
The samples were placed in tubes without anticoagulants 
and stored in room temperature for about 60 minutes — to 
complete coagulation. When the clot was fully formed, sam-
ples were centrifuged for 15 minutes at 2000 rpm. After cen-
trifugation blood samples were then placed into Eppendorf 
tubes, frozen and stored at –70°C until the assay procedure.
The research was carried out using TIMP-1 and Sur-
vivin ELISA kits from R&D Systems according to the man-
ufacturer’s recommendations. The minimum detectable 
dose (MDD) of TIMP-1 ranged from 87 to 524 ng/mL. The 
sensitivity was 0.08 ng/mL. The serum concentration of 
TIMP-1 was expressed in ng/mL. Survivin Assay Range was 
from 31.2–2.000 pg/mL and the sensitivity was 9.96 pg/mL. 
Concentration of survivin was expressed in pg/mL.
Statistical analysis
Statistical data was prepared on calculation spreadsheet 
program Microsoft Excel 2014 and the calculations were 
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done using SPSS 14.0 and MS Excel 2014. In the analyzed 
group for the individual results of measured parameters 
such as arithmetic mean, standard deviation, maximal and 
minimal values were indicated. Statistical analysis was per-
formed using analysis of variance ANOVA. P < 0.05 was the 
indicator of statistically significant difference.
The study group consisted of 29 healthy pregnant 
women in III-rd trimester of pregnancy. Mean age of the 
group was 32.17 (sd 3.83) years, minimal age was 25 years 
and maximal 38 years. The shortest gestational age was 
37 weeks, the longest was 40 weeks. Mean pregnancy age 
was 38.7 weeks (sd 0.65).
RESULTS
In study group concentration of TIMP-1 was measured in 
maternal blood serum and in umbilical cord after delivery, 
separately for arterial and vein blood serum. The results are 
presented in ng/mL on the graphs below. 
The concentration of TIMP-1 in human serum due to 
producer’s suggestion was from 87 to 524 ng/mL. Figu- 
re 1 presented TIMP-1 concentration in maternal vein blood 
in group of pregnant women.
The highest TIMP-1 concentration was 429 ng/mL the 
lowest 158.9 ng/mL. Mean value of TIMP-1 in maternal blood 
samples was 234.74 ng/mL (sd. 70.2). 
Results of TIMP-1 concentration in artery of umbilical 
cord are presented in Figure 2.
The highest TIMP-1 concentration in umbilical cord 
artery serum was 395.8 ng/mL the lowest 110.3 ng/mL. 
Mean value of TIMP-1 in maternal blood samples was 
266.823 ng/mL (sd. 67.9). 
The results of TIMP-1 concentration in umbilical cord 
vein blood is presented in Figure 3.
The highest TIMP-1 concentration in umbilical cord vein 
serum was 426.9 ng/mL the lowest 208.1 ng/mL. Mean value of 
TIMP-1 in maternal blood samples was 297.8 ng/mL (sd. 63.5). 
The results obtained from maternal blood and cord 
blood were compared and presented in Figure 4.
By comparing differences betveen TIMP-1 plasma con-
centrations from maternal blood and umbilical cord blood 
from arteries and vein done by ANOVA variancy analysis 
showed no statistical differences.
Post-hoc analysis shows again no statistical differences 
betveen compared samples of TIMP-1 (p > 0.05).
Figure 1. TIMP-1 concentration in maternal vein blood serum measured in ng/mL
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Figure 2. TIMP-1 concentration in arterial umbilical cord blood serum measured in ng/mL
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The concentrations of TIMP-1 were similar and inde-
pendent from the kind of blood vessels. Arterial values of 
TIMP-1 in umbilical cord compared to maternal and fetal 
veins were lower, but no statistical difference was found.
Presence of Survivin was found in embryonic cells and 
could be present in blood that contains fetal stem cells. Sur-
vivin concentration was measured in serum of maternal 
vein blood and umbilical cord blood separately for vein and 
arteries. The results of Survivin values in pg/ml is presented 
in Figures 5–8.
The highest Survivin concentration in maternal vein 
serum was 11.708 pg/mL, in 6 cases the results were nearly 
negative. Mean value of Survivin was 4.31 pg/mL (sd. 4.5).
The results obtained from umbilical cord arterial blood 
are presented in Figure 6.
The highest Survivin concentration from umbilical cord 
artery serum was 64.98 pg/mL, in 6 cases the results in 
maternal blood were nearly negative, we found positive 
results from 34.80 to 1.01. Only in one case the result was 
nearly 0. Mean value of Survivin was 14.03 pg/mL (sd. 17.5). 
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Figure 3. TIMP-1 concentration in vein umbilical cord blood serum measured in ng/mL
500
450
400
350
300
250
200
150
100
50
0
Co
nc
en
tr
at
io
n 
[n
g/
m
L]
Maternal blood
Arterial umbilical cord blood
Vein umbilical cord blood
Figure 4. TIMP-1 concentration in compared blood samples
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The results obtained from cord blood vein is presented 
in Figure 7.
The highest Survivin concentration from umbilical cord 
vein serum was 49.28 pg/mL. In 6 cases where the results in 
maternal blood were nearly negative we found 3 negative 
results. Mean value of Survivin was 13.16 pg/mL (sd. 13.3).
The results of Survivin concentrations obtained from 
maternal blood and cord blood are compared and presented 
in Figure 8.
By comparing differences betveen Survivin in plasma 
concentrations from maternal blood and cord blood — from 
arteries and vein done by ANOVA variancy analysis, no sta-
tistical differences were found.
Post-hoc analysis shows no statistical differences be-
tween compared samples of Survivin (p > 0.05).
The mean concentrations of Survivin were similar but we 
found that in some cases the results in cord blood serum in 
both vessels-vein and arteries were almost negative. Arterial 
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Figure 6. Survivin concentration in arterial umbilical cord blood plasma in pg/mL
60
50
40
30
20
10
0
Co
nc
en
tr
at
io
n 
[p
g/
m
L]
49.289
10.623
17.16 16.066
6.308
13.884
0.01
7.382
12.795
0.01
11.708
0.01
25.953
Figure 7. Survivin concentration in vein umbilical cord blood in pg/mL
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values of Survivin in umbilical cord compared to maternal 
blood were higher, but no statistical difference was found.
DISCUSSION
TIMP-1 is known as an active inhibitor of matrix pro-
teases and as a growth-promoting factor. Serum concentra-
tion of TIMP-1 was to our knowledge not yet measured in 
pregnant women during 3-rd trimester of pregnancy and 
compared to vein and arterial cord blood. We expected to 
find out the possible differences between maternal and 
fetal blood. The hypothesis that the distribution of serum 
TIMP-1 in fetal umbilical cord vein and artery could differ 
due to changes that may occur in placental structures was 
promising. We did not find any statistical differences be-
tween TIMP-1 concentration in arterial and vein umbilical 
blood. Comparing fetal and maternal serum concentration 
of TIMP-1 we observed no differences either. The source 
of TIMP-1 in serum due to observation of Lee and al. [12]. 
could be caused by peripheral T cell activation, as found it 
in multiple sclerosis. Authors pointed that TIMP-1 could be 
elevated in different conditions related to inflammatory 
processes and probably in our study inflammation process 
did not occur.
In two cases in maternal blood the concentration 
was high [> 300 ng/mL] in comparison with the results 
of Ylisirnio, but more often we saw high concentration of 
TIMP-1in fetal cord blood [4 cases]. In cancer high level of 
TIMP-1 is correlated to bad prognosis, but we still don’t know 
what impact for high TIMP-1 concentration for pregnancy is 
[13]. The concentration of TIMP-1 in maternal sera was lower 
than in the group of healthy patients of both gender — as 
was presented in article of Holten-Andersen M. [14].
The statistical analysis of other authors shows that the 
level of TIMP-1 protein in the sera of patients is correlated 
with gender. The serum of male patients compared with its 
concentration in female counterparts was significantly lower 
level of theTIMP-1 [15].
The presence of lower levels of TIMP-1 in pregnancy 
observed in cases of cancer could be explained by a lack 
of poor differentiation of cells and the presence of mature 
cells. Our observations confirm the results of the research 
conducted by Giaginis [16]. 
We exclude inflammatory processes in our study know-
ing that chorioamnionitis as an inflammatory process is 
correlated with an elevated tissue inhibitor of metallopro-
teinase 1 levels [17]. As Tency noticed TIMP-1 concentrations 
were lower in preterm gestation, irrespective of labor [18].
There is no difference between mean concentrations of 
TIMP-1 comparing vein and artery of umbilical cord blood 
that could suggest no inflammatory processes presence 
and no proliferation in placental circulation.
The second measured molecule was Survivin, that 
plays a regulative role in placental development. Changes 
of Survivin concentration in early pregnancy could lead 
to placental dysfunction and complications in pregnancy 
development later.
In our study mean concentrations of Survivin in maternal 
blood and in cord blood serum in both vessels-vein and ar-
teries were similar but we found that in some cases in both 
umbilical cord vessels the results were negative. Arterial 
values of Survivin in umbilical cord compared to maternal 
blood were higher, but no statistical difference was found.
In Matamitsi-Puchner study no statistically significant 
differences in Survivin concentrations in cord blood were 
observed between IUGR, LGA and AGA groups, but the 
results were obtained from mixed blood. Birth weight, cus-
tomized centile, gestational age, gender of neonate, mode 
of delivery and parity influence on Survivin concentrations 
was not found [19]. This study showed that Survivin con-
centrations in cord blood probably do not reflect the dis-
turbances of feto-placental apoptosis, expected in IUGR and 
fetal macrosomia, due to gestational DM. 
Our results of Survivin concentration in cord blood 
separately for vein and artery could be useful to establish 
reference values for full-term neonates as Malamitsi-Puchner 
suggested in her publication [19]. The continuation of analy-
sis and additional studies, reporting the concentration of 
survivin in cord blood in different pregnancy complications 
are required to answer the question how abnormal placenta-
tion process could have impact on pregnancy development.
CONCLUSIONS
In III-rd trimester of pregnancy parameters of Timp-1 and 
Survivin — anti-apoptotic substances concentration were 
similar in maternal and cord blood in both artery and vein. 
We found no increased activity of selected antiapoptotic fac-
tors. The study should be continued in larger group of patients.
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